Oncosec Medical Cm (ONCS) 1.78 $ONCS
OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016
PR Newswire - Thu Jun 09, 3:01PM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced key corporate objectives as well as financial results for the third quarter and year to date ended April 30, 2016.
ONCS: 1.78 (-0.02)
OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy
PR Newswire - Mon Jun 06, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its collaborators at the University of California San Francisco (UCSF) presented results at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating the utility of a T-cell exhaustion marker to predict response to anti-PD-1 monotherapies. Authors of this poster discussion session from UCSF include Adil Daud, MD, Alain Algazi, MD, and Michael Rosenblum, MD, PhD. This "low-tumor infiltrating lymphocyte" (TIL) marker is currently being used to select patients for the ongoing Phase II investigator-sponsored clinical trial evaluating the combination of OncoSec's investigational therapy, ImmunoPulse(TM) IL-12, and the approved anti-PD-1 therapy, pembrolizumab, in patients with unresectable metastatic melanoma.
ONCS: 1.78 (-0.02)
OncoSec Medical Incorporated's CEO Punit Dhillon Interviewed by The Life Sciences Report
Marketwire Canada - Thu Jun 02, 9:58AM CDT
SAN FRANCISCO, CA--(Marketwired - June 02, 2016) - Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's (NASDAQ: ONCS) Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.
ONCS: 1.78 (-0.02)
OncoSec to Present at Scientific and Investment Conferences in June
PR Newswire - Wed Jun 01, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in June, including:
ONCS: 1.78 (-0.02)
OncoSec Closes $10 Million At-The-Market Registered Direct Offering
PR Newswire - Thu May 26, 7:12PM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced at-the-market registered direct offering with a single healthcare dedicated institutional fund for the purchase of 5,509,642 shares of its common stock at a price of $1.815, or pre-funded warrants in lieu thereof at a price of $1.805, and warrants to purchase up to an aggregate of 5,509,642 shares of common stock at an exercise price of $1.69 per share for a term of 9 years. The warrants are immediately exercisable on the date of issuance. The offering closed on May 26, 2016.
ONCS: 1.78 (-0.02)
OncoSec Announces $10 Million At-The-Market Registered Direct Offering
PR Newswire - Mon May 23, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare dedicated institutional fund to purchase approximately $10 million of securities in an at-the-market registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 5,509,642 shares of its common stock, or pre-funded warrants in lieu thereof, at a price of $1.815 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 5,509,462 shares of common stock at an exercise price of $1.69 per share for a term of 9 years. The warrants are immediately exercisable on the date of issuance.
ONCS: 1.78 (-0.02)
OncoSec to Host Third Quarter Financial Results Conference Call on June 9, 2016
PR Newswire - Wed May 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal third quarter 2016 financial results conference call on Thursday, June 9 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 4148915. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: ir.oncosec.com/events.
ONCS: 1.78 (-0.02)
4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.82 (-0.30), UNXL: 1.52 (+0.02), ONCS: 1.78 (-0.02), OCLS: 0.96 (-0.03)
OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Tue Apr 19, 3:45PM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse(TM) IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy. These data suggest that ImmunoPulse(TM) IL-12 may prime and enhance response rates to PD-1/PD-L1 blockade. Alain Algazi, MD, skin cancer specialist in the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center, presented the findings in an oral presentation entitled "Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma" (Abstract #CT134) at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans, LA.
ONCS: 1.78 (-0.02)
OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).
HTBX: 0.60 (+0.02), ONCS: 1.78 (-0.02)
OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data
PR Newswire - Wed Apr 13, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a webcast to provide an overview and panel discussion regarding new clinical data that will be featured as an oral presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting. The webcast will be held on Wednesday, April 20, 2016 at 11:00 AM ET/8:00 AM PT.
ONCS: 1.78 (-0.02)
OncoSec Announces Poster Presentation with Heat Biologics, Inc. at the American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Tue Apr 12, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that preclinical results from OncoSec's collaboration with Heat Biologics, Inc. will be featured as a poster presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA.
ONCS: 1.78 (-0.02)
Trending Stocks: We've Found Four to Observe on Tuesday, March 22nd
ACCESSWIRE - Tue Mar 22, 10:09AM CDT
MIAMI, FL / ACCESSWIRE / March 22, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch. MTSL, ONCS, COOL, and CTRV have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CTRV: 0.92 (unch), COOL: 0.88 (+0.01), ONCS: 1.78 (-0.02), MTSL: 1.10 (unch)
OncoSec Announces Presentation at Upcoming American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Thu Mar 17, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that new clinical data will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA.
ONCS: 1.78 (-0.02)
OncoSec to Present at 28th Annual ROTH Conference
PR Newswire - Thu Mar 10, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at the 28th Annual ROTH Conference on Wednesday, March 16, 2016. The presentation is scheduled to begin at 8:00 AM PT at The Ritz Carlton, Orange County.
ONCS: 1.78 (-0.02)
OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2016 and Calendar 2016 Milestones
PR Newswire - Tue Mar 08, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced key corporate objectives as well as financial results for the second quarter and year to date ended January 31, 2016.
ONCS: 1.78 (-0.02)
OncoSec's Punit Dhillon Named "Most Admired CEO" by San Diego Business Journal
PR Newswire - Fri Feb 19, 11:35AM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that Chief Executive Officer Punit Dhillon received the honor of being named "2016 Most Admired CEO" by the San Diego Business Journal in the Small Public Company category.
ONCS: 1.78 (-0.02)
OncoSec to Present at Prominent Investment Conferences in February
PR Newswire - Wed Feb 03, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in February, including:
ONCS: 1.78 (-0.02)
Immunotherapy Inside the Cell Interview by The Life Sciences Report
Marketwired - Fri Jan 08, 8:00AM CST
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies -- and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc. -- with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.
ONCS: 1.78 (-0.02), SRNE: 6.44 (-0.31)
OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016
PR Newswire - Thu Jun 09, 3:01PM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced key corporate objectives as well as financial results for the third quarter and year to date ended April 30, 2016. ONCS: 1.78 (-0.02)
OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy
PR Newswire - Mon Jun 06, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its collaborators at the University of California San Francisco (UCSF) presented results at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating the utility of a T-cell exhaustion marker to predict response to anti-PD-1 monotherapies. Authors of this poster discussion session from UCSF include Adil Daud, MD, Alain Algazi, MD, and Michael Rosenblum, MD, PhD. This "low-tumor infiltrating lymphocyte" (TIL) marker is currently being used to select patients for the ongoing Phase II investigator-sponsored clinical trial evaluating the combination of OncoSec's investigational therapy, ImmunoPulse(TM) IL-12, and the approved anti-PD-1 therapy, pembrolizumab, in patients with unresectable metastatic melanoma. ONCS: 1.78 (-0.02)
OncoSec Medical Incorporated's CEO Punit Dhillon Interviewed by The Life Sciences Report
Marketwire Canada - Thu Jun 02, 9:58AM CDT
SAN FRANCISCO, CA--(Marketwired - June 02, 2016) - Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's (NASDAQ: ONCS) Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.
ONCS: 1.78 (-0.02)
OncoSec to Present at Scientific and Investment Conferences in June
PR Newswire - Wed Jun 01, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in June, including: ONCS: 1.78 (-0.02)
OncoSec Closes $10 Million At-The-Market Registered Direct Offering
PR Newswire - Thu May 26, 7:12PM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced at-the-market registered direct offering with a single healthcare dedicated institutional fund for the purchase of 5,509,642 shares of its common stock at a price of $1.815, or pre-funded warrants in lieu thereof at a price of $1.805, and warrants to purchase up to an aggregate of 5,509,642 shares of common stock at an exercise price of $1.69 per share for a term of 9 years. The warrants are immediately exercisable on the date of issuance. The offering closed on May 26, 2016. ONCS: 1.78 (-0.02)
OncoSec Announces $10 Million At-The-Market Registered Direct Offering
PR Newswire - Mon May 23, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare dedicated institutional fund to purchase approximately $10 million of securities in an at-the-market registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 5,509,642 shares of its common stock, or pre-funded warrants in lieu thereof, at a price of $1.815 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 5,509,462 shares of common stock at an exercise price of $1.69 per share for a term of 9 years. The warrants are immediately exercisable on the date of issuance. ONCS: 1.78 (-0.02)
OncoSec to Host Third Quarter Financial Results Conference Call on June 9, 2016
PR Newswire - Wed May 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal third quarter 2016 financial results conference call on Thursday, June 9 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 4148915. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: ir.oncosec.com/events. ONCS: 1.78 (-0.02)
4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.82 (-0.30), UNXL: 1.52 (+0.02), ONCS: 1.78 (-0.02), OCLS: 0.96 (-0.03)
OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Tue Apr 19, 3:45PM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse(TM) IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy. These data suggest that ImmunoPulse(TM) IL-12 may prime and enhance response rates to PD-1/PD-L1 blockade. Alain Algazi, MD, skin cancer specialist in the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center, presented the findings in an oral presentation entitled "Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma" (Abstract #CT134) at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans, LA. ONCS: 1.78 (-0.02)
OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org). HTBX: 0.60 (+0.02), ONCS: 1.78 (-0.02)
OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data
PR Newswire - Wed Apr 13, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a webcast to provide an overview and panel discussion regarding new clinical data that will be featured as an oral presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting. The webcast will be held on Wednesday, April 20, 2016 at 11:00 AM ET/8:00 AM PT. ONCS: 1.78 (-0.02)
OncoSec Announces Poster Presentation with Heat Biologics, Inc. at the American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Tue Apr 12, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that preclinical results from OncoSec's collaboration with Heat Biologics, Inc. will be featured as a poster presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA. ONCS: 1.78 (-0.02)
Trending Stocks: We've Found Four to Observe on Tuesday, March 22nd
ACCESSWIRE - Tue Mar 22, 10:09AM CDT
MIAMI, FL / ACCESSWIRE / March 22, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch. MTSL, ONCS, COOL, and CTRV have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CTRV: 0.92 (unch), COOL: 0.88 (+0.01), ONCS: 1.78 (-0.02), MTSL: 1.10 (unch)
OncoSec Announces Presentation at Upcoming American Association for Cancer Research (AACR) Annual Meeting 2016
PR Newswire - Thu Mar 17, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that new clinical data will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA. ONCS: 1.78 (-0.02)
OncoSec to Present at 28th Annual ROTH Conference
PR Newswire - Thu Mar 10, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at the 28th Annual ROTH Conference on Wednesday, March 16, 2016. The presentation is scheduled to begin at 8:00 AM PT at The Ritz Carlton, Orange County. ONCS: 1.78 (-0.02)
OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2016 and Calendar 2016 Milestones
PR Newswire - Tue Mar 08, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced key corporate objectives as well as financial results for the second quarter and year to date ended January 31, 2016. ONCS: 1.78 (-0.02)
OncoSec's Punit Dhillon Named "Most Admired CEO" by San Diego Business Journal
PR Newswire - Fri Feb 19, 11:35AM CST
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that Chief Executive Officer Punit Dhillon received the honor of being named "2016 Most Admired CEO" by the San Diego Business Journal in the Small Public Company category. ONCS: 1.78 (-0.02)
OncoSec to Present at Prominent Investment Conferences in February
PR Newswire - Wed Feb 03, 5:00AM CST
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in February, including: ONCS: 1.78 (-0.02)
Immunotherapy Inside the Cell Interview by The Life Sciences Report
Marketwired - Fri Jan 08, 8:00AM CST
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies -- and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc. -- with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.
ONCS: 1.78 (-0.02), SRNE: 6.44 (-0.31)
